FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	DC	20549	
wasnington,	D.C.	20549	

STATEMENT OF CHANCES	IN DENETICIAL OWNERSHIP
STATEMENT OF CHANGES	IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Chauhan Jyoti						2. Issuer Name and Ticker or Trading Symbol Landos Biopharma, Inc. [LABP]							(Chec	k all application	able)	g Pers	on(s) to Issu 10% Ow Other (s	ner		
	NDOS BIO	First) PHARMA, INC. 7E, SUITE 216	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/26/2021							X	below)	.0	below) Operation	·			
(Street)	SBURG V	Ά	24060 (Zip)		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ind Line) X	Form fil	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Da			Date	Transaction ate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed (ties Acquired (A) or I Of (D) (Instr. 3, 4 an		or and 5)	5. Amoun Securities Beneficia Owned Fo	s For ally (D) ollowing (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									V	Amount	(A) or (D) Pri		rice	Transacti (Instr. 3 a	on(s)			(111501.4)		
Common Stock			07/26	5/2021		М		118,0	118,054 A S		\$1.86	209,299			D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y		ode (I	ansaction Derivative Descrities		Derivative E: Securities (N Acquired (A) or Disposed of (D) (Instr.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				Cod		v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amo or Num of Sh	ber		(Instr. 4)	on(a)			
Stock Option (right to buy)	\$1.86	07/26/2021			М			118,054	(1)		10/19/2030	Common Stock	118	,054	\$0.00	155,68	31	D		

1. 91,245 shares of common stock underlying this option vested and became exercisable on January 1, 2021 and the remaining 182,490 shares of common stock underlying this option vest and become exercisable thereafter in 24 equal monthly installments, subject to the Reporting Person's continuous service with the Issuer on each such date.

Remarks:

/s/ Jyoti Chauhan

11/18/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.